Skip to main
BVS

Bioventus (BVS) Stock Forecast & Price Target

Bioventus (BVS) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bioventus is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and has a diverse portfolio of products in areas such as pain treatments, surgical solutions, and restorative therapies. Despite a recent reimbursement cut for one of its products, Bioventus has maintained strong financial guidance for 2026, demonstrating management's confidence in the company's momentum. With a strong focus on investing in growth drivers and reducing debt, the company is poised for mid to high single-digit revenue growth and has potential for M&A opportunities in the future.

Bears say

Bioventus is facing a significant top-line headwind in FY/26, estimated to be around $2-3 million, primarily due to a recent Medicare reimbursement cut. While the company delivered strong Q4 results, with top-line revenue and profitability beating expectations, its restorative therapies segment showed a decline of 26.0%. Although management expects this segment to grow in 2026, the recent divestiture of the Advanced Rehab business and associated headwind distorts the results, and the company's overall growth outlook remains uncertain in the face of continued market challenges. Additionally, with a high level of debt and uncertain cash flows, there are concerns about the financial stability of Bioventus in the long term.

Bioventus (BVS) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioventus (BVS) Forecast

Analysts have given Bioventus (BVS) a Buy based on their latest research and market trends.

According to 3 analysts, Bioventus (BVS) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioventus (BVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.